12:00 AM
 | 
May 26, 2014
 |  BC Week In Review  |  Company News  |  Deals

AADi, Celgene deal

Celgene granted AADi an exclusive, worldwide license to develop and commercialize Celgene's ABI-009, a nanoparticle albumin-bound (nab) formulation of rapamycin, also known as sirolimus. Financial terms are not disclosed. AADi founder, President and...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >